162 related articles for article (PubMed ID: 24762546)
1. Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer.
Krohn A; Freudenthaler F; Harasimowicz S; Kluth M; Fuchs S; Burkhardt L; Stahl P; C Tsourlakis M; Bauer M; Tennstedt P; Graefen M; Steurer S; Sirma H; Sauter G; Schlomm T; Simon R; Minner S
Mod Pathol; 2014 Dec; 27(12):1612-20. PubMed ID: 24762546
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer.
Kluth M; Meyer D; Krohn A; Freudenthaler F; Bauer M; Salomon G; Heinzer H; Michl U; Steurer S; Simon R; Sauter G; Schlomm T; Minner S
Oncotarget; 2016 Jan; 7(4):3897-904. PubMed ID: 26684029
[TBL] [Abstract][Full Text] [Related]
3. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
[TBL] [Abstract][Full Text] [Related]
4. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.
Yoshimoto M; Ding K; Sweet JM; Ludkovski O; Trottier G; Song KS; Joshua AM; Fleshner NE; Squire JA; Evans AJ
Mod Pathol; 2013 Mar; 26(3):435-47. PubMed ID: 23018874
[TBL] [Abstract][Full Text] [Related]
5. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA
Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259
[TBL] [Abstract][Full Text] [Related]
6. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.
Han B; Mehra R; Lonigro RJ; Wang L; Suleman K; Menon A; Palanisamy N; Tomlins SA; Chinnaiyan AM; Shah RB
Mod Pathol; 2009 Aug; 22(8):1083-93. PubMed ID: 19407851
[TBL] [Abstract][Full Text] [Related]
7. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
8. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
[TBL] [Abstract][Full Text] [Related]
9. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
[TBL] [Abstract][Full Text] [Related]
10. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.
Bhalla R; Kunju LP; Tomlins SA; Christopherson K; Cortez C; Carskadon S; Siddiqui J; Park K; Mosquera JM; Pestano GA; Rubin MA; Chinnaiyan AM; Palanisamy N
Mod Pathol; 2013 Jun; 26(6):835-48. PubMed ID: 23348902
[TBL] [Abstract][Full Text] [Related]
11. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
12. Frequency of PTEN alterations, TMPRSS2-ERG fusion and their association in prostate cancer.
Fallahabadi ZR; Noori Daloii MR; Mahdian R; Behjati F; Shokrgozar MA; Abolhasani M; Asgari M; Shahrokh H
Gene; 2016 Jan; 575(2 Pt 3):755-60. PubMed ID: 26424596
[TBL] [Abstract][Full Text] [Related]
13. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.
Haffner MC; Weier C; Xu MM; Vaghasia A; Gürel B; Gümüşkaya B; Esopi DM; Fedor H; Tan HL; Kulac I; Hicks J; Isaacs WB; Lotan TL; Nelson WG; Yegnasubramanian S; De Marzo AM
J Pathol; 2016 Jan; 238(1):31-41. PubMed ID: 26331372
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
[TBL] [Abstract][Full Text] [Related]
15. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
Pust A; Kylies D; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Salomon G; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Krech T; Schlomm T; Melling N
Hum Pathol; 2016 Feb; 48():102-10. PubMed ID: 26614400
[TBL] [Abstract][Full Text] [Related]
16. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.
Scheble VJ; Braun M; Beroukhim R; Mermel CH; Ruiz C; Wilbertz T; Stiedl AC; Petersen K; Reischl M; Kuefer R; Schilling D; Fend F; Kristiansen G; Meyerson M; Rubin MA; Bubendorf L; Perner S
Mod Pathol; 2010 Aug; 23(8):1061-7. PubMed ID: 20473283
[TBL] [Abstract][Full Text] [Related]
17. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
[TBL] [Abstract][Full Text] [Related]
18. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
Leinonen KA; Saramäki OR; Furusato B; Kimura T; Takahashi H; Egawa S; Suzuki H; Keiger K; Ho Hahm S; Isaacs WB; Tolonen TT; Stenman UH; Tammela TL; Nykter M; Bova GS; Visakorpi T
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2333-44. PubMed ID: 24083995
[TBL] [Abstract][Full Text] [Related]
19. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.
Reid AH; Attard G; Brewer D; Miranda S; Riisnaes R; Clark J; Hylands L; Merson S; Vergis R; Jameson C; Høyer S; Sørenson KD; Borre M; Jones C; de Bono JS; Cooper CS
Mod Pathol; 2012 Jun; 25(6):902-10. PubMed ID: 22460813
[TBL] [Abstract][Full Text] [Related]
20. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.
Carver BS; Tran J; Gopalan A; Chen Z; Shaikh S; Carracedo A; Alimonti A; Nardella C; Varmeh S; Scardino PT; Cordon-Cardo C; Gerald W; Pandolfi PP
Nat Genet; 2009 May; 41(5):619-24. PubMed ID: 19396168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
